About Us
ClavystBio’s mission is to accelerate life sciences translation and innovation in Singapore.
We invest in early-stage biotech , medtech and digital health ventures, as well as in real estate and services to build global life sciences companies.
ClavystBio is established by CLA Real Estate Holdings, a wholly-owned subsidiary of Temasek.
Our People
We draw on our diverse experience and global relationships

Michelle EVARISTO
Chief Operating Officer
Read BioMichelle has been instrumental in forming ClavystBio and shaping the company’s strategy. She brings over 17 years of experience in finance and operations.
Michelle is currently seconded from Temasek International where she was most recently Director (Enterprise Development Group). She has been with Temasek since 2010 and has had past roles in Investments (Financial Services) and the Investment Group Office. Prior to Temasek, Michelle was an investment banker at Credit Suisse Singapore and Credit Suisse New York.
Michelle holds a BSc in Management Engineering (Honorable Mention) from the Ateneo de Manila University, Philippines, and an MBA (with Distinction) from Johnson Graduate School of Management, Cornell University, USA. She is also an alumna of London Business School, UK (exchange programme).

Wen Qi HO
Director, Investments and New Ventures
Read BioWen Qi focuses on investing in and building global healthcare companies from Singapore. She was previously CEO at Lightstone Ventures, where she played a major role in establishing the firm’s presence in Singapore. Wen Qi evaluated new investment opportunities in the biopharmaceutical and medical device sectors, and was actively involved in venture-building portfolio companies in Singapore such as Medisix Therapeutics, Allay Therapeutics and Ligature Therapeutics.
Wen Qi is an advocate for early career researcher participation in biotech entrepreneurship, and serves on advisory and grant review panels with leading institutions in Singapore. She also serves on boards of ClavystBio’s portfolio companies.
Wen Qi attained her PhD in Immunology at Stanford University, and BSc in Molecular and Cellular Biology at Johns Hopkins University.

Sang SHIN
Director, Business Development
Read BioSang has spent his career disrupting, developing and rethinking systems. At ClavystBio, his focus is to build a digital health innovation engine that will help catalyse collaboration between ecosystem constituents.
Sang was previously Director (Enterprise Development Group) at Temasek International. He introduced and fostered tech innovations at Temasek and its portfolio companies through accelerators, labs, and global startup ecosystem partnerships. Before joining Temasek, Sang held positions at GIC, Bridgewater Associates, and McKinsey & Company.
Prior to moving to Singapore, Sang was based in Silicon Valley where he co-founded Been, Inc and developed the world’s only mobile app that enabled users to monetise and control their personal data and privacy.
Sang holds a BA in Economics, and BSc in Environmental Science from Tufts University, USA.

Yingmin WANG
Director,
Business Development
Yingmin brings the rigour of a scientist to business strategy. She has led business development, partnerships and R&D in hi-tech sectors such as life sciences, agrifood and semiconductors. Her passion for accelerating technology translation into healthcare solutions brought her to ClavystBio, where she drives the development of bioprocessing programmes.
Yingmin’s experience spans both the private and public sector. She has held positions at Applied Materials South East Asia, the Singapore Economic Development Board and A*Star.
Yingmin attained her PhD in Bioengineering from the California Institute of Technology (Caltech), USA, and BSc in Biomedical Engineering from Duke University, USA.

Yvonne KOH
Vice President, Investments & New Ventures
Read BioYvonne brings a unique blend of commercial and public sector experience to investing and venture building at ClavystBio. Her multi-faceted career includes roles in venture capital investing, business strategy, product development, technology commercialization, and innovation policy across the biotech and medtech sectors.
Yvonne was previously at Lightstone Ventures (LSV) and was involved in due diligence and program management for the firm’s early-stage ventures globally and in Singapore. Prior to that, Yvonne was Deputy Director at the National Research Foundation where she led the development and implementation of Singapore’s innovation strategy. She has also held operational roles at a Singapore-based medical diagnostics start-up.
Yvonne attained her PhD in Biochemistry from the University of Wisconsin Madison, USA, and a BSc in Molecular Biology from the University of Illinois Urbana-Champaign, USA.

Patricia LEE
Vice President, Corporate Communications and Marketing
Read BioPatricia is a storyteller. She believes in broadening people’s perspectives and bridging differences through stories. She is excited about ClavystBio’s mission to drive health impact, and inspiring ever-expanding networks and communities with new ideas and knowledge.
Patricia began her career as a journalist, working for the Daily Telegraph magazine, Financial Times How to Spend It, and SPH magazines. Prior to joining ClavystBio, she oversaw content development at National Gallery Singapore, and taught journalism at LASALLE College of the Arts and Singapore Polytechnic. She has contributed to titles including T: The New York Times Style Magazine, Monocle, and The Straits Times.
Patricia holds an LLB (Hons) from the London School of Economics and Political Science, UK

Shin Bin LIM
Vice-President,
Business Development
Shin Bin oversees the development of medtech programmes at ClavystBio.
She was previously a medical officer at the Ministry of Health (Singapore), and Resident at Singapore National Eye Centre.
Shin Bin holds an MBBS (Medicine) and BA (Law) from the University of Cambridge, UK, and MMed (Opthamology) from National University of Singapore. She was awarded the President’s Scholarship by the Public Service Commission of Singapore in 2008.

Nge Hwee NG
Vice-President,
Business Development
Nge Hwee drives the development of shared business services for ClavystBio’s portfolio companies, and looks at improving the connectivity of players within the life sciences ecosystem. A founding member of the team, she is energised by the zero-to-one environment of setting up a new platform, and the potential impact of ClavystBio’s work.
Nge Hwee is currently seconded from Temasek International where she was most recently Vice President (Enterprise Development Group). She has been with Temasek since 2014. Prior to Temasek, Nge Hwee was with the Corporate Finance and Valuations teams at PricewaterhouseCoopers.
Nge Hwee holds a double degree in Business and Accountancy (First Class Honours) from Nanyang Technological University, Singapore.

Nigel TEH
Assistant Vice-President,
Business Development
Nigel focuses on growing ClavystBio’s business and investment platforms. He is a believer in biology as technology for human wellness, and excited about building the next generation of life sciences innovations through Singapore.
Nigel previously ran venture building and investment platforms for large multinationals and private family offices. Prior to that, he worked at the Singapore Economic Development Board managing the Republic’s inbound investments in the chemicals, synthetic biology and food industries. He played a key role in originating investments, as well as developing national infrastructure to ensure the long term success of these industries.
Nigel holds a BA in Management (Magna Cum Laude) from Singapore Management University. Alongside his work in ClavystBio, Nigel is also the founder of Next Billion Burgers, a global movement to create an open source community in the plant-based food industry, with a goal of enabling plant-based foods that are affordable, nutritious and sustainable.

Regis ONG
Manager, Lab Facilities and Safety
Read BioRegis is overseeing the development of ClavystBio’s lab facility and infrastructure at Science Park. A champion for co-working labs, he sees them as the solution to the huge gap between spin-offs and manufacturing that many scientists fail to overcome. “They solve the primary problem of the sheer expense of building a lab, and allow scientists to do what they do best – bump heads and collaborate to generate new ideas.”
Prior to joining ClavystBio, Regis was Technical Head for Fuchs Singapore and a founding team member of Life Science Incubator. He also has extensive experience managing quality control for leading pharma MNCs.
Regis holds a Bsc in Biomedical Sciences from the University of Bradford, UK.

Samantha YEO
Manager, Finance and Compliance
Read BioSamantha supports ClavystBio on finance and compliance matters. She believes that finance is a powerful tool in ensuring company growth and ongoing success.
Samantha started her career in the Governance, Risk and Advisory team at KPMG, gaining experience in enterprise risk management, compliance review and internal audit reviews in Singapore and overseas. She then joined Lightstone Ventures, where she focused on setting up and supporting the smooth running of finance functions and operations in early-stage life science ventures.
Samantha holds a BAcc with a second major in Finance from Singapore Management University.

Charles Yiliu ZHANG
Senior Associate, Investment & New Ventures
Read BioCharles is energized by the accelerating pace of innovation in biomedical research, and the potential of fledgling startups to create life changing medicines and devices. At ClavystBio, he draws upon his diverse background in science, intellectual property (IP), and venture investment to help scientists and start-ups create lasting impact for patients across the world.
Charles started his career as a post-doctoral research scientist at the Institute of Cell & Molecular Biology (IMCB), A*STAR and later worked as a trainee patent attorney at an international firm. Before joining ClavystBio, Charles was in a Singapore based biotech VC focusing on venture creation and investment.
Charles attained his PhD in Cell and Molecular Biology from the National University of Singapore (NUS), and BSc in Life Science from Sun Yat-sen University, China. He also holds a Graduate Certificate in IP from the Faculty of Law, NUS and IP Academy Singapore.

Sophia LEE
Executive Secretary
Read BioSophia makes the trains run on time at ClavystBio. She specialises in administrative technology, and manages schedules and provides administrative support to the CEO and team.
Sophia has over 10 years of experience working alongside senior management in financial institutions and MNCs including Temasek International, NETS and EY.

Fidah ALSAGOFF
Chairman
Read BioDr Fidah Alsagoff is Joint Head of the Enterprise Development Group (Singapore) and Head of Life Sciences at Temasek International.
He was previously a Partner at Innosight Ventures Pte Ltd and prior to that, was Chief Executive Officer of Ministry of Health Holdings. Fidah’s career also includes nearly a decade in social entrepreneurship where he established several programmes and enterprises catering to unmet healthcare needs of patients. The latest among these was the Singapore Cord Blood Bank.
Fidah graduated from the National University of Singapore with a Bachelors of Medicine and Surgery, and later with a Masters of Medicine in Public Health. He attended INSEAD on a Lee Kuan Yew Scholarship for post-graduate studies, and subsequently graduated with an Executive MBA (with distinction). As valedictorian of his EMBA class, he was awarded the Claude Janssen Prize.
Fidah currently serves on the Board of Trustees of the Singapore University of Technology and Design, and on the Governing Board of the Duke-NUS Medical School.

Ken EHLERT
Independent Director
Read BioKen spent the early years of his career working across the industries of agriculture, finance, and retail, before finding a home in healthcare. Since then, he has focused on using data, analytics, and a longitudinal understanding of disease to build products and businesses that improve the healthcare system. His career spans three decades and consists of numerous leadership positions and entrepreneurial endeavors, including serving as UnitedHealth Group’s Chief Scientific Officer.
Ken has founded and successfully exited several companies, including All Savers—a novel insurance product for small businesses that brings the advantages of large groups, Motion—the first pay[1]for-healthy-behaviors insurance program that used biosensors, Level2—the first insurance plan that combines disease-specific interventions with benefit design, and Savvysherpa—a healthcare R&D firm focused at the intersection of math, clinical science, and human connection.
Today, Ken is most passionate about the linkage between cognition, behavior, biology, and chronic diseases. His efforts are aimed at exploring this linkage and harnessing it to improve health and access to healthcare, especially for those who are socio-economically challenged.

Ranga KRISHNAN
Independent Director
Read BioDr Ranga Krishnan is Senior Advisor to the Rush University System for Health in Chicago, and Chairman of the National Medical Research Council (NMRC) in Singapore.
He was previously Dean of Rush Medical College, and Chief Executive Officer of the Rush University System for Health. Ranga advanced the innovation of care delivery by organising providers around patients, diseases and conditions rather than by department or division to enable greater multidisciplinary collaboration. He also remodelled Rush’s innovation and technology strategy, including the Innovation and Technology Transfer Office which manages Rush’s intellectual properties.
Prior to Rush, Ranga was Dean of Duke-NUS Graduate Medical School Singapore, where he developed a teaching method called Team LEAD (Learn, Engage, Apply, Develop) which has since been adopted by other universities and high schools.

Miguel KO
Non-Independent Director
Read BioMiguel Ko is Chairman of CapitaLand Investment Limited, and Deputy Chairman of CLA Real Estate Holdings Pte Ltd (formerly known as Ascendas-Singbridge Pte Ltd) and CapitaLand Group Private Limited. Previously, he was the founding Group CEO of the former Ascendas-Singbridge until its combination with CapitaLand in 2019.
Miguel is widely recognised for his knowledge and insight into business and culture in Asia Pacific, particularly in the travel, leisure and property development sectors. He was voted Regional Hotel Chief of the Year in 2007 and 2008 by the readers of Travel Weekly. He was also the winner of the Visionary Leader of the Year in 2007 at the Travel Weekly Asia Industry Awards, recipient of the 2007 Global Award at the World Travel Mart in London and honoured with the Lifetime Achievement Award in 2012 at the China Hotel Investment Conference in Shanghai and again in 2021 at the Hotel Investment Conference Asia Pacific (HICAP).

Vicki SATO
Independent Director
Read BioDr Vicki Sato is a Venture Partner at ARCH Venture Partners, Chairman of Vir Biotechnology and Denali Therapeutics, and a business advisor to several enterprises in the biotechnology and pharmaceutical industries.
Vicki was previously a Professor of Management Practice at Harvard Business School and a Professor of the Practice, Molecular and Cell Biology, for Harvard’s Faculty of Arts and Sciences. Prior to that, Vicki spent many years in the industry, including most recently as President of Vertex Pharmaceuticals.
Vicki is a member of the President’s Council of Advisors on Science and Technology (PCAST) in the United States, and was the inaugural Co-Chair of the Advisory Council for the NYC LifeScience Initiative to establish New York City as a global leader in life sciences.

Amy SCHULMAN
Independent Director
Read BioAmy Schulman is a Managing Partner in Polaris Partners’ New York office and focuses on investments in healthcare companies. She also manages the Polaris Innovation Fund.
Prior to Polaris, Amy held various roles at Pfizer including President of Pfizer Consumer Healthcare, President of Pfizer Nutrition where she was instrumental in its sale to Nestle in 2012, and General Counsel of Pfizer.
Amy currently serves as Executive Chair of SQZ Biotech, and as a director of Alnylam Pharmaceuticals and Mount Sinai Hospital in New York City.

KHOO Shih
Senior Investment Advisor
Read BioKhoo Shih is Managing Director, Life Sciences Investments at Temasek, where she has more than 15 years of experience investing in private and public life sciences and healthcare companies globally.
Prior to joining Temasek, Khoo Shih was with UOB Venture Management and was responsible for investing in life sciences venture and growth companies in China and USA. She started her business career in the Biomedical Sciences cluster at the Singapore Economic Development Board and was part of the team that spearheaded the growth of the biomedical industry.
Khoo Shih attained her PhD in Genetics and Development from University of Texas Southwestern Medical Center, USA and a BSc in Microbiology from National University of Singapore.